Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

Fig. 1

(Adapted from Kim et al., Baggio et al. and Wang et al. [19,20,21])

Mechanism of action of antiobesity drugs. 5-HT2C-R: 5-hydroxytryptamine (serotonin) 2C receptor; ARC arcuate nucleus, CART cocaine and amphetamine-regulated transcript, D1 dopamine receptor D1, D2 dopamin receptor D2, DAT dopamine transporter, GABA gamma-aminobutyric acid, GLP-1R glucagon-like peptide-1 recepto, NPY/AgRP neurons expressing neuropeptide Y and agouti- related peptide, POMC proopiomelanocortin, μ-OR μ-opioid receptor

Back to article page